Answers are grounded in this paper and cite their sources.
Objective: Post-stroke cognitive impairment (PSCI), particularly in patients with cerebral small vessel disease (SVD), remains an important challenge. This Korean NeuroEndovascular Society (KoNES) expert consensus evaluates the rationale for combining cilostazol with standardized Ginkgo biloba extract to address vascular and cognitive aspects of post-stroke care. Methods: An expert panel formulated clinical questions and reviewed randomized trials, meta-analyses, and translational evidence. Recommendations were refined through iterative discussion and review, considering clinical applicability in South Korea. Results: Cilostazol reduces recurrent ischemic stroke risk with a relatively low risk of hemorrhagic complications and may slow white matter lesion progression. Standardized Ginkgo biloba extract, particularly EGb 761, has shown cognitive and functional benefits in selected populations. A standardized extract used in Korea has a broadly similar phytochemical composition, but direct comparative bioequivalence data are lacking. Available pharmacological and clinical evidence suggests complementary mechanisms for the combination, without a clear bleeding signal under studied conditions. Nevertheless, direct evidence of efficacy and safety for combined treatment in stroke populations is limited. Fixed-dose combinations may reduce pill burden when both treatments are indicated. Conclusions: Combining cilostazol with standardized Ginkgo biloba extract may offer a multi-target approach for stroke survivors with SVD or PSCI. Its clinical use should acknowledge the limitations of indirect evidence; prospective randomized trials are needed to establish long-term efficacy and safety.
No takes yet. Share an insight, caveat, or question.
Choi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: